Tirzepatide for treating type 2 diabetes (TA924)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Last updated: 1 September 2025Published: 25 October 2023
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Published: 5 June 2019
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Published: 27 March 2019
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Last updated: 23 November 2016Published: 26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Published: 23 November 2016
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Published: 25 May 2016
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Published: 25 March 2015
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)Status:In consultationProgramme:Technology appraisal guidanceConsultation end date: 18 March 2026Published: 25 June 2014